NCT05275946 is a Phase 1 clinical trial of Targeted alpha therapy in Thyroid Cancer, sponsored by Osaka University.

Who is sponsoring NCT05275946?

NCT05275946 is sponsored by Osaka University.

What drugs are being tested in NCT05275946?

Interventions in NCT05275946: Targeted alpha therapy.

What condition does NCT05275946 study?

NCT05275946 studies Thyroid Cancer.

Is NCT05275946 still recruiting?

NCT05275946 is currently completed. Last updated 24 April 2025.

Last reviewed 2025-04-24 · How we verify

NCT05275946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer

Completed Phase 1 Last updated 24 April 2025

What this trial tests

Phase 1 trial testing Targeted alpha therapy in Thyroid Cancer in 11 participants. Completed in 31 March 2025.

Timeline

20 November 2021

Primary endpoint
31 December 2024

31 March 2025

Quick facts

Lead sponsor	Osaka University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	20 November 2021
Primary completion	31 December 2024
Estimated completion	31 March 2025
Sites	1 location across Japan

Drugs / interventions tested

Targeted alpha therapy — full drug profile →

Conditions studied

Thyroid Cancer — all drugs for Thyroid Cancer →

Sponsor

Osaka University

Who can join

Under 18, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single intravenous administration of TAH-1005 is performed in patients with differentiated thyroid cancer (papillary cancer, follicular cancer) who cannot obtain therapeutic effect with standard treatment or who have difficulty in implementing and continuing standard treatment. The safety, pharmacokinetics, absorbed dose, and efficacy will be evaluated to determine the recommended dose for Phase II clinical trial.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted Alpha-Particle Therapy: A Review of Current Trials.
Jang A, Kendi AT, Johnson GB, Halfdanarson TR, et al · · 2023 · cited 59× · PMID 37511386 · DOI 10.3390/ijms241411626
Astatine-211 based radionuclide therapy: Current clinical trial landscape.
Albertsson P, Bäck T, Bergmark K, Hallqvist A, et al · · 2022 · cited 46× · PMID 36687417 · DOI 10.3389/fmed.2022.1076210
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.
Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, et al · · 2023 · cited 37× · PMID 36344651 · DOI 10.1007/s00259-022-06016-z
Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition).
Ukon N, Higashi T, Hosono M, Kinuya S, et al · · 2022 · cited 14× · PMID 35794455 · DOI 10.1007/s12149-022-01765-1
Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.
Watabe T, Kaneda-Nakashima K, Kadonaga Y, Ooe K, et al · · 2024 · cited 13× · PMID 38891856 · DOI 10.3390/ijms25115667
Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics.
Munekane M, Fuchigami T, Ogawa K. · · 2024 · cited 13× · PMID 38564087 · DOI 10.1007/s44211-024-00514-w
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.
Sharma S, Pandey MK. · · 2023 · cited 13× · PMID 37895931 · DOI 10.3390/ph16101460
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
Watabe T, Kabayama K, Naka S, Yamamoto R, et al · · 2023 · cited 13× · PMID 37827841 · DOI 10.2967/jnumed.123.266313

Verify or expand the search:

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Other Osaka University trials

Trials by the same sponsor.

NCT06924151 — Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients · NA · recruiting
NCT06826027 — TAV-in-SAV in Japanese Patients · active not recruiting
NCT06441994 — Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer · Phase 1 · recruiting
NCT05939661 — A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer · Phase 2 · recruiting
NCT05350098 — Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05275946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Osaka University
Last refreshed: 24 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05275946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing